India global research hub for diabetes and genetic disorders: Dr. Jitendra Singh

Shubham Kumar
2 Min Read
India global research hub for diabetes

India global research hub for diabetes and next-generation healthcare solutions has gained strong momentum, Union Minister of State Dr. Jitendra Singh announced on Friday. Specifically, over a dozen diabetes-related research projects are currently underway through the Department of Biotechnology (DBT) and CSIR under the Ministry of Science and Technology. Furthermore, Dr. Singh shared these insights while inaugurating RSSDI 2026 in Bengaluru before leading clinicians, academicians, and international researchers.

Indigenous healthcare breakthroughs and youth prevention

Dr. Singh noted that India’s vast population and genetic diversity create unique opportunities to build globally relevant medical solutions. However, he cautioned that preventing obesity and diabetes among Indian youth represents a vital national responsibility extending beyond the medical fraternity. Additionally, India has transformed from relying on external treatments to developing indigenous vaccines, antibiotics, biosimilars, and genetic therapies.

Research & Innovation AreaKey Government & Startup Initiatives
Active Diabetes ProjectsOver a dozen initiatives via DBT and CSIR
Indigenous BiosimilarsProgress in liraglutide and insulin Lispro
Next-Gen Insulin DeliveryTemperature-resilient insulin and startup oral insulin
Genomic & Precision ResearchIndia Genome Study and molecular-level interventions

Moreover, the minister highlighted that precision medicine and molecular interventions open fresh pathways for understanding and preventing Type 2 diabetes.

Public-private collaboration and affordable treatment

Dr. Singh invited deeper collaboration among government institutes, private researchers, clinicians, startups, and medical associations to accelerate healthcare innovation. Specifically, he praised startup efforts exploring oral insulin alongside institutional work on temperature-resilient insulin to simplify storage and transport.

Consequently, indigenous progress in biosimilars like liraglutide and insulin Lispro strengthens affordable treatment access nationwide. Therefore, as India global research hub for diabetes initiatives advance, the country has solidified its position as a frontline contributor to global medical science.

Share This Article
Follow:

Shubham Kumar is a dedicated journalist and reporter specializing in the infrastructure sector at InfraInsiders. With a strong academic foundation in journalism, a robust background in digital content research for top-tier creators, and a deep-seated passion for urban development, Shubham covers critical sectors driving India's growth.

Core Beat & Reporting Areas

  • Real Estate: Market trends, housing policies, commercial developments, and urban housing dynamics.
  • Railways & Metros: Expansion projects, modernization initiatives, high-speed rail developments, and urban mass rapid transit systems.
  • Infrastructure: Large-scale public works, policy shifts, logistics corridors, and capital investments shaping the country's physical landscape. Professional Experience.

Reporter | InfraInsiders (Current) Reporting on real estate, railways, metro, and broader infrastructure developments. Content Researcher | Leading YouTubers and Instagram Influencers (Previous) Conducted in-depth research, fact-checking, and trend analysis to support high-impact digital video content and social media campaigns for prominent creators. Education Bachelor of Arts in Journalism and Mass Communication (BJMC) Institution: Indira Gandhi National Open University (IGNOU) Focus: Equipped with core media principles, news reporting ethics, digital media production, and broadcast communication.

He can be reached out at:

Email : shubhamscribe28@gmail.com
LinkedIn : https://www.linkedin.com/in/shubham-kumar-137857438/
X : https://x.com/ShubhamScribe

Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *